CDD-0097
| CDD-0097 | |
|---|---|
| [[File:|frameless|220px|alt=|Chemical structure of CDD-0097]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
CDD-0097 is an investigational drug currently under development for the treatment of neurodegenerative disorders. It is a small molecule compound that has shown promise in preclinical studies for its potential neuroprotective and anti-inflammatory effects.
Mechanism of Action[edit]
CDD-0097 is believed to exert its effects by modulating specific neurotransmitter pathways and reducing oxidative stress in neuronal cells. The exact mechanism of action is still under investigation, but it is hypothesized to involve the inhibition of pro-inflammatory cytokines and the enhancement of neurotrophic factors.
Pharmacokinetics[edit]
The pharmacokinetic profile of CDD-0097 has been characterized in animal models. It exhibits good oral bioavailability and a favorable half-life, allowing for once-daily dosing. The compound is metabolized primarily in the liver and excreted via the renal route.
Clinical Trials[edit]
CDD-0097 is currently in Phase II clinical trials. Early results have shown a significant improvement in cognitive function in patients with mild to moderate Alzheimer's disease. The trials are also assessing the safety and tolerability of the drug in a larger patient population.
Potential Side Effects[edit]
While CDD-0097 has been generally well-tolerated in clinical trials, some patients have reported mild gastrointestinal disturbances and headaches. Long-term safety data is still being collected.
Research and Development[edit]
The development of CDD-0097 is being led by a consortium of academic institutions and pharmaceutical companies. The research is funded by grants from various governmental and non-governmental organizations dedicated to advancing treatments for neurodegenerative diseases.
Future Directions[edit]
Further studies are planned to explore the efficacy of CDD-0097 in other neurodegenerative conditions such as Parkinson's disease and Huntington's disease. Researchers are also investigating potential combination therapies with existing treatments to enhance therapeutic outcomes.
Also see[edit]
- Neurodegenerative disease
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
- Neuroprotection
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
